← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Dynport Vaccine Company, Llc
Frederick, MD
$70,222,637
Total funding
10
Grants
Funding over time
peak $6.2M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$70,222,637 · 10
By mechanism
N01$43,697,700 · 7
UC1$15,384,534 · 2
U01$11,140,403 · 1
Investigators at Dynport Vaccine Company, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Phase 2 Trial for Venezuelan Equine Encephalitis V3526$9,996,228
UC1 · FY2004 · AI
Vitrification-stabilized Multivalent Botulinum Vaccines$5,388,306
UC1 · FY2004 · AI
Phase I Clinical Trial Unit for Therapeutics$4,689,593
N01 · FY2008 · AI
PHASE 1 CLINICAL TRIALS UNITS FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES: EVALUATION OF THERAPEUTICS FOR NEISSERIA GONORRHOEAE$4,083,461
N01 · FY2017 · AI
Phase I Clinical Trial Unit for Therapeutics$3,622,483
N01 · FY2012 · AI
Fast-Track Production of a Heptavalent Botulinum Vaccine$3,134,091
U01 · FY2004 · AI
Fast-Track Production of a Heptavalent Botulinum Vaccine$2,997,064
U01 · FY2005 · AI
Fast-Track Production of a Heptavalent Botulinum Vaccine$2,813,296
U01 · FY2006 · AI
Phase I Clinical Trial Unit for Therapeutics$2,690,939
N01 · FY2013 · AI
Phase I Clinical Trial of a Therapeutic for Gram Negative Bacteria Infection$2,675,212
N01 · FY2021 · AI
Phase I Clinical Trial Unit for Therapeutics$2,398,050
N01 · FY2013 · AI
Phase 1 Clinical Trial: Carbapenem-resistant Enterbacterales (CRE)$2,320,888
N01 · FY2022 · AI
Phase I Clinical Trial Unit for Therapeutics$2,261,800
N01 · FY2014 · AI
Fast-Track Production of a Heptavalent Botulinum Vaccine$1,907,093
U01 · FY2003 · AI
Phase 1 Clinical Trial Unit for Therapeutics$1,811,584
N01 · FY2014 · AI
EARLY PHASE CLINICAL TRIAL UNITS (EPCTU): PHASE I CLINICAL TRIAL TO EVALUATE A SARS-COV-2 THERAPEUTIC$1,800,783
N01 · FY2023 · AI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases: Evaluation of Therapeutics for MERS-CoV$1,530,675
N01 · FY2017 · AI
Task B1: Phase 1 Clinical Trial: Carbapenem-resistant Enterbacterales (CRE) Infections$1,019,192
N01 · FY2023 · AI
Phase 1 Clinical Trial: Carbapenem-resistant Enterbacterales (CRE) Infections$971,302
N01 · FY2022 · AI
Phase I Clinical Trial Unit for Therapeutics$960,000
N01 · FY2012 · AI